Prevention of Recurrent Preterm Delivery by 17 Alpha-Hydroxyprogesterone Caproate (MFMU Progesterone Trial)
Source: View publication →
In pregnant women with a history of spontaneous preterm delivery, weekly intramuscular injections of 17 alpha-hydroxyprogesterone caproate (17-OHPC) significantly reduced the risk of recurrent preterm birth compared to placebo.
Key Findings
Study Design
Study Limitations
Clinical Significance
This landmark trial temporarily transformed obstetric practice by establishing 17-OHPC as the standard of care for preventing recurrent spontaneous preterm birth, leading to the FDA's accelerated approval of Makena. However, its clinical significance was ultimately reversed when the much larger confirmatory PROLONG trial (2020) failed to replicate these benefits, resulting in the FDA withdrawing 17-OHPC from the market in 2023.
Historical Context
Prior to 2003, preventative options for recurrent preterm birth were limited. The dramatic findings of this MFMU Network trial led to rapid endorsement by the American College of Obstetricians and Gynecologists (ACOG) and the 2011 FDA accelerated approval of Makena (17-OHPC). As a condition of accelerated approval, the FDA mandated a larger confirmatory trial (PROLONG). Published in 2020, the PROLONG trial (n=1,708) found no significant difference in preterm birth <35 weeks (11.0% with 17-OHPC vs. 11.5% with placebo). Consequently, following extensive review and public hearings, the FDA officially withdrew its approval for Makena in April 2023, representing one of the most prominent reversals in modern obstetric practice.
Guided Discussion
High-yield insights from every perspective
Physiologically, how does progesterone help maintain a normal pregnancy, and based on these mechanisms, why was 17 alpha-hydroxyprogesterone caproate (17-OHPC) hypothesized to prevent recurrent spontaneous preterm birth?
Key Response
Progesterone is essential for maintaining uterine quiescence. It prevents myometrial contractility by downregulating the formation of gap junctions, decreasing the expression of oxytocin receptors, and suppressing the local inflammatory pathways that lead to early cervical ripening and labor initiation. Supplementation was hypothesized to artificially prolong this quiescent state in women prone to premature labor.
Based on the original MFMU trial, what was the specific indication for 17-OHPC, and how does this clinical indication differ from the current indication for vaginal progesterone?
Key Response
The MFMU trial targeted women with a prior history of spontaneous preterm birth (a historical risk factor). In contrast, vaginal progesterone is classically indicated for women discovered to have a short cervix on transvaginal ultrasound during the current pregnancy (an anatomical risk factor), regardless of their prior obstetrical history. Distinguishing between history-indicated and ultrasound-indicated interventions is a frequent board testing point.
The 2003 MFMU trial demonstrated significant efficacy for 17-OHPC, yet the much larger 2019 PROLONG trial failed to replicate these findings. What were the key demographic and baseline risk differences between these two study populations that likely explain this dramatic discrepancy?
Key Response
The MFMU trial consisted of a high-risk, predominantly US-based population with a high proportion of Black women, and an unusually high recurrent preterm birth rate in the placebo group (~54% at <37 weeks). The PROLONG trial was an international study, predominantly White, with a much lower baseline preterm birth rate in the placebo group (~11%). This highlights how varying baseline risk levels can fundamentally alter absolute risk reduction and the replicability of trial findings.
Following the FDA's 2023 withdrawal of Makena (17-OHPC) due to the PROLONG trial results showing lack of efficacy, how should you counsel a pregnant patient with a history of spontaneous preterm birth who previously received and 'benefited' from 17-OHPC in a successful prior pregnancy?
Key Response
Counseling requires validating her previous experience while explaining that larger, newer datasets indicate the drug does not actually reduce neonatal morbidity or recurrent preterm birth, suggesting her prior success was likely the natural course of that pregnancy. Counseling should then pivot to current evidence-based management, prioritizing serial transvaginal cervical length screening and offering a cerclage or vaginal progesterone if cervical shortening occurs.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MFMU trial was stopped early by the Data and Safety Monitoring Board (DSMB) due to apparent efficacy. How does early termination for benefit introduce methodological bias, and how might this 'winner's curse' have impacted the perception of 17-OHPC's efficacy for nearly two decades?
Key Response
Stopping a trial early for benefit often captures a 'random high' in the data, leading to an overestimation of the true treatment effect size (the 'winner's curse'). This inflated effect size misguides future power calculations and establishes a false, overly optimistic sense of robust efficacy that frequently fails to hold up in larger, fully completed replication studies.
A critical reviewer of the 2003 MFMU trial might flag the preterm birth rate of 54.9% (at <37 weeks) in the placebo group. Why is this specific statistic a major threat to the internal validity and interpretability of the relative risk reduction reported?
Key Response
A 54.9% recurrence rate is remarkably higher than historical cohorts for recurrent preterm birth, which typically hover around 20-30%. If a control group experiences an uncharacteristically high rate of the primary outcome (due to chance, unmeasured confounding, or selection bias), the intervention will artificially appear highly protective. Editors must scrutinize whether the control arm represents the true standard natural history.
Given the trajectory from the 2003 MFMU trial to the 2019 PROLONG trial and the 2023 FDA withdrawal of 17-OHPC, how have ACOG and SMFM guidelines been forced to shift, and what does this illustrate about the process of updating clinical guidelines based on post-market confirmatory trials?
Key Response
Historically, guidelines provided a strong recommendation for 17-OHPC based on the MFMU trial. Following PROLONG and the FDA withdrawal, ACOG and SMFM updated their guidance to state that 17-OHPC is no longer recommended for preterm birth prevention. This illustrates the critical importance of 'living' guidelines and Level A evidence updates that can reverse long-standing clinical dogma when FDA-mandated post-market phase 4 trials fail to demonstrate clinical benefit.
Clinical Landscape
Noteworthy Related Trials
PREGNANT Trial
Tested
Vaginal progesterone gel (90 mg daily)
Population
Asymptomatic singleton pregnancies with a short cervix (10-20 mm)
Comparator
Placebo gel
Endpoint
Preterm birth <33 weeks of gestation
OPPTIMUM Trial
Tested
Vaginal progesterone (200 mg daily)
Population
Singleton pregnancies at high risk of preterm birth
Comparator
Placebo
Endpoint
Birth <34 weeks, neonatal composite morbidity/death, and childhood cognitive score
PROLONG Trial
Tested
17-alpha-hydroxyprogesterone caproate (17-OHPC)
Population
Singleton pregnancies with a history of spontaneous preterm birth
Comparator
Placebo
Endpoint
Preterm birth <35 weeks and composite neonatal morbidity/mortality
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis